Closing a $12 Million Margin Gap Without Cutting Clinical Staff
Valley Ridge Medical Center is a 340-bed hospital nine months into FY25. Volume is within 1% of budget, but the operating margin is -1.4% against a budgeted +3.2%. The CFO's variance packet shows four drivers: agency and travel nurse spend of $6.8 million against a $2.1 million budget; supply inflation of 7.8%; denial write-offs of $4.9 million, up 41%; and a payer mix shift in which Medicare Advantage now accounts for 29% of inpatient days (up from 18%), with 12% of MA claims denied for medical necessity versus 3% for traditional Medicare. The board directs the executive team to close a $12 million gap. Two constraints are non-negotiable: no reduction in direct-care RN or respiratory therapy FTEs, and no suspension of the 1.5% merit increase already promised for the January cycle, worth about $3.6 million. The VP of nursing proposes eliminating the new-graduate residency program ($1.1 million) and the shared-governance education budget.
1. How should the executive team structure the $12 million gap-closing analysis so that the reductions are not simply an across-the-board 8% cut to every department?
Read the worked answer
An across-the-board 8% cut treats a strategic problem as arithmetic. Structure the analysis by variance type:
- Volume vs. price vs. mix vs. productivity. Volume is on budget, so the gap is price, mix, and productivity. The MA shift from 18% to 29% is a price-and-mix problem, not a supply problem, and supply cuts cannot close it.
- Rank opportunities by savings, speed, quality risk, and reversibility, not by departmental politics. Build three tiers: no-regret (supply standardization and physician preference-item review, formulary management, converting overtime to an internal float pool, denial prevention); strategic (service-line margin review, MA contract terms, revenue-cycle automation); and last resort (program elimination).
- Work the revenue side before expense. A $4.9 million denial pool growing 41% is recoverable cash; if even 15% is preventable, that is more than $700,000 recurring with no clinical risk. Apply the same logic to charge capture, clinical documentation integrity, and underpayment recovery.
- Protect margin-producing capacity. Across-the-board cuts hit the profitable and unprofitable service line equally, and they usually take the education budget that prevents $50,000 turnover events.
- Separate one-time from recurring. Selling an asset or drawing reserves closes FY25 but not FY26.
Deliverable: one ranked portfolio showing recurring savings, one-time items, FTE impact, quality risk, owners, and dates; approve in tranches with a 60-day re-forecast.
2. The denial data suggest the Medicare Advantage problem is a contract and process issue rather than a clinical one. What would you do in the next 90 days, and how would you measure success?
Read the worked answer
Assume the denials are largely administrative until proven otherwise.
Diagnose: stratify the $4.9 million by payer, denial reason (medical necessity, prior authorization, coding, timely filing, duplicate), service line, and physician. Calculate the appeal overturn rate. An overturn rate above roughly 40% is evidence that the denials are not clinically justified and moves the conversation from process to contract.
Ninety-day actions:
- Centralize prior authorization for high-volume MA services, with real-time eligibility checks at scheduling so authorization failures are caught before the service, not after.
- Add a physician advisor program for medical-necessity peer-to-peer reviews; track response times against contract requirements.
- Run documentation and coding audits on the top ten denial DRGs.
- Automate appeal workflow and track days-to-appeal; most contracts have short filing windows that quietly write off recoverable cash.
Contract levers: request the prior-authorization code list, require peer-to-peer review within a defined period, clarify readmission attribution, and add a data-discrepancy process with a reconciliation timeline.
Measures: initial denial rate, overturn rate, days to appeal, net collection rate, and cost to collect. Guard against a false win: writing off small claims improves the rate without recovering any cash.
3. The two board constraints remove most of the available savings. How should the executive team respond, and what should it ask the board to reconsider?
Read the worked answer
Cost the constraints honestly and return with a decision, not a workaround.
Quantify the residual. With direct-care FTEs and the $3.6 million merit increase off the table, roughly $4.5 to $5 million of controllable expense remains. The team cannot credibly find $12 million in that space without cutting clinical supplies, delaying maintenance, or thinning support services that protect quality.
Present a menu with explicit trade-offs:
- Defer or stage the $9 million inpatient bed renovation and the EHR module upgrade, with the operational consequences stated.
- Restructure non-clinical overhead: management span of control, purchased services, vendor contracts, and length-of-stay reduction.
- Reconsider the merit increase: a 0.75% adjustment plus a targeted pool for hard-to-fill roles saves roughly $1.8 million and preserves the message.
- Accept a lower FY25 margin target with a credible FY26 recovery plan, funded partly from reserves, rather than booking fictitious savings.
Name the risk of silence. If the team absorbs the gap through vague productivity targets, the cuts will land on whatever is least defended, which is usually clinical supply and staff development. The board set constraints without seeing their price; the executive's job is to show that price clearly and let the board choose, documenting the decision.